The estimated Net Worth of Emil D Kakkis is at least $180 Milion dollars as of 3 September 2024. Emil Kakkis owns over 20,000 units of Ultragenyx Pharmaceutical stock worth over $125,277,075 and over the last 21 years he sold RARE stock worth over $47,791,998. In addition, he makes $6,586,480 as President, Chief Executive Officer oraz Director at Ultragenyx Pharmaceutical.
Emil has made over 48 trades of the Ultragenyx Pharmaceutical stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of RARE stock worth $1,117,000 on 3 September 2024.
The largest trade he's ever made was selling 75,000 units of Ultragenyx Pharmaceutical stock on 25 November 2008 worth over $1,198,500. On average, Emil trades about 12,532 units every 87 days since 2003. As of 3 September 2024 he still owns at least 2,223,985 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Emil Kakkis stock trades at the bottom of the page.
Dr. Emil D. Kakkis M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to Ultragenyx, Dr. Kakkis served from September 1998 to February 2009 in various executive capacities, and ultimately as Chief Medical Officer, at BioMarin Pharmaceutical Inc., a biopharmaceutical company. Dr. Kakkis then served as a development consultant to BioMarin from 2009 through 2010. Dr. Kakkis is also Founder of EveryLife Foundation for Rare Diseases, a non-profit organization he started in 2009 to accelerate biotechnology innovation for rare diseases. Dr. Kakkis is board certified in Medical Genetics and was board certified in Pediatrics. He holds a B.A. in Biology from Pomona College and received combined M.D. and Ph.D. degrees from the UCLA School of Medicine’s Medical Scientist Training Program where he received the Bogen prize for his research. Kakkis possesses specific expert knowledge of genetics and rare diseases and operational experience in the life sciences sector that qualify him to serve on our Board.
As the President, Chief Executive Officer oraz Director of Ultragenyx Pharmaceutical, the total compensation of Emil Kakkis at Ultragenyx Pharmaceutical is $6,586,480. There are no executives at Ultragenyx Pharmaceutical getting paid more.
Emil Kakkis is 59, he's been the President, Chief Executive Officer oraz Director of Ultragenyx Pharmaceutical since . There are 7 older and 16 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Emil's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr oraz Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: